Overview
Introduction
As the reimbursement status for the cost of hospital-acquired infections is
under pressure by payors, interest in preventing these complications at the
outset is growing. Nosocomial vaccines offer one route of prevention. This
report assesses the clinical pipeline candidates five key nosocomial pathogens
and their potential market environment including target population size
estimates.
Scope
- In-depth analysis of epidemiology, spread, costs and reimbursement linked
to nosocomial infections across the major Western markets
- Thorough general and pathogen-specific assessment of the market potential
for the major 5 classes of nosocomial vaccines
- In-depth discussion and sizing estimates of potential target groups for
nosocomial vaccines by pathogen
- Review of alternative strategies for infection prevention and comparison
with vaccination
Report Highlights
The increasing incidence and severity of nosocomial infections has sparked an
interest in preventive strategies such as vaccination. High costs and
reimbursement cuts associated with nosocomial infections provide a strong
incentive for healthcare stakeholders to invest in infection prevention,
providing a strong rationale for vaccine development.
In the highly cost-conscious nosocomials market, a prudent definition of
vaccination target groups will be crucial to satisfy the stringent
cost-benefit analysis. Whereas patients undergoing planned hospital stays will
benefit from vaccination, alternative prevention methods may be preferable for
immuno-compromised, newborn and acute patients.
Datamonitor believes that C. difficile vaccines will have the easiest route to
market due to the large and well-defined target population and a high unmet
need. Vaccines against S. aureus and P. aeruginosa could prove valuable in
selected target groups, whereas there is only a limited potential for vaccines
against S. epidermidis and enterococcus.
Reasons to Purchase
- Review the epidemiological, clinical and economical factors driving new
product decisions in nosocomial vaccine development.
- Gain insight into the pipeline through a discussion of key candidates in
clinical development for five nosocomial pathogens.
- Understand and identify key market opportunities by reviewing sizing
estimates for key target populations by pathogen.
| 
View Cart
